High Cost Therapy Profile: December 2024 - Prime Therapeutics
High Cost Therapy Profile: December 2024
Treatment of Steroid-Refractory Acute Graft vs. Host Disease (SR-aGVHD) – Pediatrics
Prime Therapeutics’ High-Cost Therapy Profile analyzes the financial impact and utilization trends of expensive medications, particularly specialty drugs. It provides insights into cost drivers, clinical value, and strategies to manage spending while maintaining patient access to essential treatments.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn.